Posted On: 01/08/2016 3:58:06 PM
Post# of 72443
Here is the Silver Lining! If you want to say Kevetrin is a hoax perpetrated by Dr. Menon the bashers have to account for the fact that the Patent has now been updated to show Aruda as an inventor as well. Why would someone fight to have their name on the patent of a hoax drug? Also his credentials have to be added to the science behind Kevetrin. Mr Aruda was apparently no slouch as evidenced by the following. Where a reporter viewed him as an authority on implant coatings (like brilacidin )
F1ash Tuesday, 07/07/15 11:18:42 PM
Re: None
Post # of 135990
File this under (just an interesting side note) . I was looking at Wayne Aruda and ran across this old article. I thought it was interesting in that he was referenced as a credible source concerning drug coated implants. Perhaps his knowledge in this area will give him reason, outside of Kevetrin, to hold more shares of CTIX.
I also noted the filing indicated both he and his wife have rights to 7.4% of the outstanding shares, I wonder if that would exempt them from the 5% rule (3.7% each)? Comments LoneRanger?
"Last week, the company began a large recall of some of its blockbuster product and of an earlier version of the stent, because of difficulty deflating their balloons when removing them from patients. The company, blaming a manufacturing defect, said the deflation problems have been linked to three deaths and 43 injuries.
Stents are small wire-mesh tubes used to prop open clogged arteries, implanted through a common surgical procedure known as angioplasty. Patients who have already received the stent are not affected by the recall.
Unlike the trouble with deflating balloons, Boston Scientific doesn't know why the balloons and drug-coated stents seemed to stick together in some cases, LaViolette said. He said the company received more reports about problems stemming from stickiness than deflation. He added that reviews are still underway."
"Wayne O. Aruda, president of Agrenetics, a Wilmington medical-devices consulting company, suggested the stickiness may be a result of Boston Scientific's rush to get thousands of stents onto the market as soon as regulators approved Taxus in March. The company has shipped about 600,000.
''I would be suspicious that maybe someone said, 'Get these things out the door,' and maybe the drying or the aging steps weren't adequate, or the packaging might have been a little different," Aruda said.
Boston Scientific, in response to Aruda's comments, said it continues to look for the cause of the stickiness problem"
http://www.boston.com/yourlife/health/disease...?page=full
F1ash Tuesday, 07/07/15 11:18:42 PM
Re: None
Post # of 135990
File this under (just an interesting side note) . I was looking at Wayne Aruda and ran across this old article. I thought it was interesting in that he was referenced as a credible source concerning drug coated implants. Perhaps his knowledge in this area will give him reason, outside of Kevetrin, to hold more shares of CTIX.
I also noted the filing indicated both he and his wife have rights to 7.4% of the outstanding shares, I wonder if that would exempt them from the 5% rule (3.7% each)? Comments LoneRanger?
"Last week, the company began a large recall of some of its blockbuster product and of an earlier version of the stent, because of difficulty deflating their balloons when removing them from patients. The company, blaming a manufacturing defect, said the deflation problems have been linked to three deaths and 43 injuries.
Stents are small wire-mesh tubes used to prop open clogged arteries, implanted through a common surgical procedure known as angioplasty. Patients who have already received the stent are not affected by the recall.
Unlike the trouble with deflating balloons, Boston Scientific doesn't know why the balloons and drug-coated stents seemed to stick together in some cases, LaViolette said. He said the company received more reports about problems stemming from stickiness than deflation. He added that reviews are still underway."
"Wayne O. Aruda, president of Agrenetics, a Wilmington medical-devices consulting company, suggested the stickiness may be a result of Boston Scientific's rush to get thousands of stents onto the market as soon as regulators approved Taxus in March. The company has shipped about 600,000.
''I would be suspicious that maybe someone said, 'Get these things out the door,' and maybe the drying or the aging steps weren't adequate, or the packaging might have been a little different," Aruda said.
Boston Scientific, in response to Aruda's comments, said it continues to look for the cause of the stickiness problem"
http://www.boston.com/yourlife/health/disease...?page=full
(0)
(0)Scroll down for more posts ▼
